Mustang Bio is a clinical-stage biopharmaceutical company that aims at curing hematologic cancers, solid tumors, and rare genetic diseases by translating medical breakthroughs in cell and gene therapies. Its pipeline comprises gene therapy programs for rare genetic disorders, CAR T therapies for hematologic malignancies and solid tumors. Mustang Bio is working on developing various programs such as the MB-101 CAR T cell program for glioblastoma, MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome and MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to the brain.